✦ LIBER ✦

Axitinib and sorafenib in second-line treatment of advanced renal cell carcinoma

✍ Scribed by Jame Abraham

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness of Sorafenib for Seco

✍ Martin Hoyle; Colin Green; Jo Thompson-Coon; Zulian Liu; Karen Welch; Tiffany Mo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB

Axitinib versus sorafenib as second-line

✍ Motzer, Robert J; Escudier, Bernard; Tomczak, Piotr; Hutson, Thomas E; Michaelso 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 316 KB

Comparative effectiveness of axitinib ve

✍ Brian I Rini; Bernard Escudier; Piotr Tomczak; Andrey Kaprin; Cezary Szczylik; T 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 363 KB

A Cost-Effectiveness Analysis of Axitini

✍ Stillman, I.O.; Ambavane, A.; Cislo, P. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Treatment outcomes of sorafenib for firs

✍ Takeshi Ueda; Yusuke Imamura; Atsushi Komaru; Satoshi Fukasawa; Tomokazu Sazuka; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 253 KB

Re: Comparative Effectiveness of Axitini

✍ Patrick A. Kenney; Christopher G. Wood 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB